ST. LOUIS, MO — Medical technology company Stereotaxis announced today that it is firmly committed to reaching the financial targets it has already set for itself. The company, which specializes in robotic magnetic navigation systems, confirmed that its 2026 goal of over $40 million in annual revenue remains precisely what it was when they first declared it.

“Our strategy is clear: we will continue to do the things we believe will lead to our desired outcomes,” stated CEO David Fischel in a press release that was notably devoid of new information. “We are confident that if we execute our plan, we will achieve the results our plan predicts.” Industry analysts noted the bold circular logic, praising its resilience against external factors like market shifts or actual performance.

Sources close to the company, who wished to remain anonymous to avoid being asked to explain the obvious, confirmed that the manufacturing ramp-up and product innovation mentioned in the announcement are indeed the same manufacturing ramp-up and product innovation that have been discussed internally for months. “It’s less of a new initiative and more of a continued initiative,” explained one insider, polishing a trophy engraved with 'Most Consistent PowerPoint Slides.'

Shareholders reportedly reacted with a mixture of relief and mild confusion, with one investor, Brenda Chen, commenting, “So, they’re going to do what they said they were going to do? That’s… good, I guess?” The company plans to continue projecting future success until future success is achieved, or until a new, equally confident projection is required.